Connect Biopharma (CNTB) News Today

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 15,500 shares, a drop of 44.2% from the June 15th total of 27,800 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 83,900 shares, the short-interest ratio is currently 0.2 days.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 27,800 shares, a decrease of 21.5% from the May 31st total of 35,400 shares. Based on an average daily volume of 114,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's stock are short sold.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 35,400 shares, a drop of 34.6% from the May 15th total of 54,100 shares. Approximately 0.1% of the company's shares are sold short. Based on an average daily volume of 118,800 shares, the days-to-cover ratio is presently 0.3 days.

BML Capital Management LLC acquired a new position in Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,061,438 shares of the company's sto

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Equities researchers at HC Wainwright boosted their FY2024 earnings estimates for shares of Connect Biopharma in a note issued to investors on Wednesday, April 17th. HC Wainwright analyst E. Bodnar now anticipates that the company w

HC Wainwright raised their price target on Connect Biopharma from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 115,500 shares, a growth of 7.5% from the March 15th total of 107,400 shares. Approximately 0.2% of the company's shares are short sold. Based on an average daily volume of 158,600 shares, the short-interest ratio is presently 0.7 days.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for Connect Biopharma in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst T. Smith now forecasts that the company will p

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 107,400 shares, a decline of 13.2% from the February 29th total of 123,700 shares. Approximately 0.2% of the company's stock are sold short. Based on an average daily trading volume, of 133,300 shares, the days-to-cover ratio is currently 0.8 days.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - HC Wainwright issued their FY2023 earnings estimates for shares of Connect Biopharma in a note issued to investors on Monday, March 4th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.70) per share for the

HC Wainwright began coverage on shares of Connect Biopharma in a report on Monday. They set a "buy" rating and a $7.00 price target for the company.

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for Connect Biopharma in a report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post e

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Stock analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for Connect Biopharma in a report released on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.44) per

Connect Biopharma (NASDAQ:CNTB) Shares Up 4%